Skip to main content

Table 1 Study schema for single-dose and multiple-dose escalation stagesa

From: Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

Stage dose and route

Patients, n(active:placebo)

SAD stage dose, route (cohort)

 

   0.3 IV (A)

4:1

   1.0 IV (B)

4:1

   1.0 SC (C)

4:1

   3.0 IV (D)

4:1

   3.0 SC (E)

4:1

   5.0 IV (F)

4:1

MAD stage dose, route (cohort)

 

   1.0 SC (G)

8:2

   3.0 SC (H)

16:4

   5.0 IV (I)

4:1

  1. aIV = intravenously; MAD = multiple ascending doses; SAD = single ascending dose; SC = subcutaneously.